Výsledky vyhledávání - Sive, Jonathan
- Zobrazuji výsledky 1 - 12 z 12
-
1
-
2
High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry Autor Sayar, Zara, Weatherill, Anna, Keddie, Stephen, Sive, Jonathan, Lunn, Michael P., Thomas, Mari, D’Sa, Shirley
Vydáno 2020Text -
3
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiv... Autor Cook, Gordon, John Ashcroft, A, Pratt, Guy, Popat, Rakesh, Ramasamy, Karthik, Kaiser, Martin, Jenner, Matthew, Henshaw, Sarah, Hall, Rachel, Sive, Jonathan, Stern, Simon, Streetly, Matthew, Bygrave, Ceri, Soutar, Richard, Rabin, Neil, Jackson, Graham H
Vydáno 2020Text -
4
Outcomes In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC UKALL XII/ECOG2993 Trial Autor Sive, Jonathan I., Buck, Georgina, Fielding, Adele, Lazarus, Hillard M., Litzow, Mark R., Luger, Selina, Marks, David I., McMillan, Andrew, Moorman, Anthony V., Richards, Susan M., Rowe, Jacob M., Tallman, Martin S., Goldstone, Anthony H.
Vydáno 2012Text -
5
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma Autor Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh
Vydáno 2021Text -
6
COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial Autor Camilleri, Marquita, Sive, Jonathan, Wilson, William, Pang, Gavin, Jenner, Richard, Phillips, Elizabeth, Popat, Rakesh, Ramasamy, Karthik, Bygrave, Ceri, Dadaga, Tushhar, Streetly, Matthew, Cavenagh, James, Chapman, Mike, Barrington, Sally, Pike, Lucy, Owen, Roger, Clifton‐Hadley, Laura, Yong, Kwee
Vydáno 2020Text -
7
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study Autor Camilleri, Marquita, Bekris, Georgios, Sidhu, Govundeep, Buck, Caroline, Elsden, Esma, McCourt, Orla, Horder, Jackie, Newrick, Fiona, Lecat, Catherine, Sive, Jonathan, Papanikolaou, Xenofon, Popat, Rakesh, Lee, Lydia, Xu, Ke, Kyriakou, Charalampia, Rabin, Neil, Yong, Kwee, Fisher, Abigail
Vydáno 2022Text -
8
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy Autor Chan, Wei Yee, Sanchez, Emilie, Chavda, Selina J., Lecat, Catherine S. Y., Ainley, Louise, Xu, Ke, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Kyriakou, Charalampia, Sive, Jonathan, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Lee, Lydia, Nastouli, Eleni, Yong, Kwee L.
Vydáno 2021Text -
9
OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines Autor Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina, Dowling, Emma, Correia, Nuno, Lecat, Catherine, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Nastouli, Eleni, Yong, Kwee, Xu, Ke
Vydáno 2021Text -
10
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease fac... Autor Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina J., Dowling, Emma, Correia, Nuno, Lecat, Catherine S. Y., McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Nastouli, Eleni, Yong, Kwee L., Xu, Ke
Vydáno 2021Text -
11
Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors Autor Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina J, Dowling, Emma, Correia, Nuno, Lecat, Catherine SY, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh D., Popat, Rakesh, Rabin, Neil K, Nastouli, Eleni, Yong, Kwee, Xu, Ke
Vydáno 2021Text -
12
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature Autor Chapman, Michael A., Sive, Jonathan, Ambrose, John, Roddie, Claire, Counsell, Nicholas, Lach, Anna, Abbasian, Mahnaz, Popat, Rakesh, Cavenagh, Jamie D., Oakervee, Heather, Streetly, Matthew J., Schey, Stephen, Koh, Mickey, Willis, Fenella, Virchis, Andres E., Crowe, Josephine, Quinn, Michael F., Cook, Gordon, Crawley, Charles R., Pratt, Guy, Cook, Mark, Braganza, Nivette, Adedayo, Toyin, Smith, Paul, Clifton-Hadley, Laura, Owen, Roger G., Sonneveld, Pieter, Keats, Jonathan J., Herrero, Javier, Yong, Kwee
Vydáno 2018Text